Minerva Neurosciences, Inc (NASDAQ:NERV) headquartered in Waltham, will host a conference call for the investment community to discuss the 3Q20 earnings result on 2nd November 2020 at 8:30 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.minervaneurosciences.com
Earnings Expectation
Minerva Neurosciences, Inc is reporting third quarter financial results on Monday 2nd November 2020, before market open.
According to analysts surveyed by Thomson Reuters, NERV is expected to report 3Q20 loss of $ 0.23 per share. For the full year, analysts anticipate top line of $ 41.19 million, while looking forward to loss of $ 0.01 per share bottom line.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The companys lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD.
